Related Experiment Video
Updated: Jun 17, 2026
07:35
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
Published on: October 11, 2018
Biomarker qualification via public-private partnerships
Clinical Pharmacology and Therapeutics
|December 19, 2009
Summary
Adiponectin effectively predicts glycemic control in diabetic patients using PPAR agonists. This highlights the value of public-private partnerships for validating biomarkers in drug development.
Area of Science:
- Biomarker discovery and validation
- Pharmacology and therapeutics
- Clinical trial data analysis
Background:
- Biomarkers are crucial for assessing drug safety and efficacy in development.
- Validating biomarkers often necessitates large datasets from randomized clinical trials.
- The Biomarkers Consortium facilitated this research using multi-company data.
Discussion:
- Adiponectin was identified as a predictive biomarker for glycemic control.
- The study focused on diabetic patients treated with peroxisome proliferator-activated receptor (PPAR) agonists.
- Findings were published in Clinical Pharmacology & Therapeutics in December 2009.
Key Insights:
- Adiponectin serves as an early indicator of treatment response.
- Public-private collaborations accelerate biomarker qualification.
- This research demonstrates a successful model for biomarker validation.
Outlook:
- Further research can explore adiponectin's role in other therapeutic areas.
- The model can be applied to qualify other predictive biomarkers.
- Strengthened partnerships can enhance drug development efficiency.
More Related Videos
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
08:01Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
Published on: November 30, 2022